Logo image of CGEM

CULLINAN THERAPEUTICS INC (CGEM) Stock Fundamental Analysis

USA - NASDAQ:CGEM - US2300311063 - Common Stock

7.35 USD
+0.04 (+0.55%)
Last: 11/6/2025, 4:30:00 PM
7.35 USD
0 (0%)
After Hours: 11/6/2025, 4:30:00 PM
Fundamental Rating

3

Taking everything into account, CGEM scores 3 out of 10 in our fundamental rating. CGEM was compared to 534 industry peers in the Biotechnology industry. CGEM has a great financial health rating, but its profitability evaluates not so good. CGEM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CGEM had negative earnings in the past year.
CGEM had a negative operating cash flow in the past year.
CGEM had negative earnings in 4 of the past 5 years.
CGEM had a negative operating cash flow in each of the past 5 years.
CGEM Yearly Net Income VS EBIT VS OCF VS FCFCGEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

CGEM has a Return On Assets of -39.74%. This is comparable to the rest of the industry: CGEM outperforms 59.55% of its industry peers.
CGEM has a better Return On Equity (-42.01%) than 70.04% of its industry peers.
Industry RankSector Rank
ROA -39.74%
ROE -42.01%
ROIC N/A
ROA(3y)-12.91%
ROA(5y)-15.57%
ROE(3y)-13.78%
ROE(5y)-16.56%
ROIC(3y)N/A
ROIC(5y)N/A
CGEM Yearly ROA, ROE, ROICCGEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

CGEM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGEM Yearly Profit, Operating, Gross MarginsCGEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, CGEM has more shares outstanding
The number of shares outstanding for CGEM has been increased compared to 5 years ago.
There is no outstanding debt for CGEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGEM Yearly Shares OutstandingCGEM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CGEM Yearly Total Debt VS Total AssetsCGEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 6.97 indicates that CGEM is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 6.97, CGEM is doing good in the industry, outperforming 78.65% of the companies in the same industry.
CGEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.97
ROIC/WACCN/A
WACCN/A
CGEM Yearly LT Debt VS Equity VS FCFCGEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

CGEM has a Current Ratio of 9.83. This indicates that CGEM is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 9.83, CGEM belongs to the best of the industry, outperforming 80.71% of the companies in the same industry.
CGEM has a Quick Ratio of 9.83. This indicates that CGEM is financially healthy and has no problem in meeting its short term obligations.
CGEM has a better Quick ratio (9.83) than 80.71% of its industry peers.
Industry RankSector Rank
Current Ratio 9.83
Quick Ratio 9.83
CGEM Yearly Current Assets VS Current LiabilitesCGEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CGEM have decreased by -5.56% in the last year.
EPS 1Y (TTM)-5.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CGEM will show a decrease in Earnings Per Share. The EPS will decrease by -5.38% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-26.86%
EPS Next 2Y-10.45%
EPS Next 3Y-3.46%
EPS Next 5Y-5.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CGEM Yearly Revenue VS EstimatesCGEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
CGEM Yearly EPS VS EstimatesCGEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGEM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGEM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGEM Price Earnings VS Forward Price EarningsCGEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGEM Per share dataCGEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as CGEM's earnings are expected to decrease with -3.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.45%
EPS Next 3Y-3.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGEM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CULLINAN THERAPEUTICS INC

NASDAQ:CGEM (11/6/2025, 4:30:00 PM)

After market: 7.35 0 (0%)

7.35

+0.04 (+0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners101.87%
Inst Owner Change-1.21%
Ins Owners1.19%
Ins Owner Change0%
Market Cap434.16M
Revenue(TTM)N/A
Net Income(TTM)-206763000
Analysts87.06
Price Target26.86 (265.44%)
Short Float %12.11%
Short Ratio7.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.24%
Min EPS beat(2)-25.93%
Max EPS beat(2)9.46%
EPS beat(4)3
Avg EPS beat(4)1.28%
Min EPS beat(4)-25.93%
Max EPS beat(4)16.07%
EPS beat(8)6
Avg EPS beat(8)8.34%
EPS beat(12)9
Avg EPS beat(12)8.34%
EPS beat(16)11
Avg EPS beat(16)4.94%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.6%
EPS NY rev (1m)-2.21%
EPS NY rev (3m)-15.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-3.23
EYN/A
EPS(NY)-3.7
Fwd EYN/A
FCF(TTM)-2.9
FCFYN/A
OCF(TTM)-2.9
OCFYN/A
SpS0
BVpS8.33
TBVpS8.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.74%
ROE -42.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.91%
ROA(5y)-15.57%
ROE(3y)-13.78%
ROE(5y)-16.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.83
Quick Ratio 9.83
Altman-Z 6.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)440.88%
Cap/Depr(5y)267.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.67%
EPS Next Y-26.86%
EPS Next 2Y-10.45%
EPS Next 3Y-3.46%
EPS Next 5Y-5.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.17%
EBIT Next 3Y-1.73%
EBIT Next 5YN/A
FCF growth 1Y-5.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.32%
OCF growth 3YN/A
OCF growth 5YN/A

CULLINAN THERAPEUTICS INC / CGEM FAQ

What is the fundamental rating for CGEM stock?

ChartMill assigns a fundamental rating of 3 / 10 to CGEM.


Can you provide the valuation status for CULLINAN THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CULLINAN THERAPEUTICS INC (CGEM). This can be considered as Overvalued.


Can you provide the profitability details for CULLINAN THERAPEUTICS INC?

CULLINAN THERAPEUTICS INC (CGEM) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CGEM stock?

The Earnings per Share (EPS) of CULLINAN THERAPEUTICS INC (CGEM) is expected to decline by -26.86% in the next year.